Designation based on phase III HAVEN 3 study demonstrating Hemlibra prophylaxis significantly reduced bleeds compared to no prophylaxis First medicine to show superior efficacy compared to prior factor VIII prophylaxis in an intra-patient comparison BASEL, 19-Apr-2018 — /EuropaWire/ — Roche … Read the full press release
Posted in Healthcare, Netherlands, Pharma & Biotech, Switzerland
Tagged Breakthrough Therapy, haemophilia, Hemlibra, inhibitors, medicines, Roche, Sandra Horning MD
New study combining Esbriet (pirfenidone) and nintedanib showing similar safety profile for the combination treatment to that expected for each treatment alone A second, retrospective, post-hoc, analysis suggests that treatment with Esbriet may be associated with a reduction of multiple … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged Esbriet, idiopathic pulmonary fibrosis, nintedanib, respiratory diseases, Roche, Sandra Horning MD
BASEL, 14-Sep-2017 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced data for the phase III BRIM8 study, which was designed to investigate the efficacy and safety of Zelboraf® (vemurafenib) in the adjuvant (after surgery) treatment of people with … Read the full press release
Posted in Healthcare, Pharma & Biotech, Sweden
Tagged BRIM8, melanoma, phase III BRIM8 study, Roche, Sandra Horning MD
Positive phase III results for Roche’s emicizumab in haemophilia A published in The New England Journal of Medicine HAVEN 1 showed emicizumab reduced bleed rate by 87% compared with on-demand bypassing agents All 12 secondary endpoints in HAVEN 1 were … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged Haemophilia A, NEJM, Roche, Roche's HAVEN 1, Sandra Horning MD, The New England Journal of Medicine
First and only cancer immunotherapy approved in advanced bladder cancer as initial treatment for those unable to receive cisplatin chemotherapy BASEL, 24-Apr-2017 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the US Food and Drug Administration (FDA) … Read the full press release
Posted in Healthcare, Pharma & Biotech, Switzerland
Tagged bladder cancer, FDA, Roche, Sandra Horning MD, TECENTRIQ
New results from the phase III GALLIUM study which compared Gazyva/Gazyvaro (obinutuzumab) plus chemotherapy to Rituxan/ MabThera (rituximab) plus chemotherapy in previously untreated follicular lymphoma will be presented in the Plenary Scientific Session New results for Venclexta/Venclyxto(venetoclax) and investigational medicine … Read the full press release
15 oral presentations from 17 abstracts across six autoimmune conditions First presentation of Actemra/RoActemra data from GiACTA – the largest ever clinical trial in people with giant cell arteritis (GCA), a condition for which there has been no approved therapy … Read the full press release
Posted in Healthcare, Pharma & Biotech, Science, Switzerland
Tagged 2016 ACR/ARHP, Actemra®/RoActemra®, Rituxan®/MabThera®, Roche, Sandra Horning MD
Data showed that over 90 percent of Japanese people in the study responded to treatment with alectinib BASEL, 11-7-2014 — /EuropaWire/ — Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) has approved … Read the full press release
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?